Fasting Triglycerides: What Your Number Changes About Your Treatment

What Is a Fasting Triglyceride Test?

A fasting triglyceride result tells you and your clinician how much triglyceride, a type of fat, is circulating in your blood after you have gone without food for at least 9 to 12 hours. The fasting requirement matters. Non-fasting samples routinely run 20-30 mg/dL higher and can reach 50 mg/dL above your true baseline, making classification unreliable. The test is drawn as part of a standard lipid panel and is used to gauge metabolic syndrome risk, MASLD (metabolic-dysfunction-associated steatotic liver disease), cardiovascular disease risk, and to guide prescribing decisions.

Why Triglycerides Are a Women's-Health Number, Not Just a "Heart" Number

Triglycerides are more predictive of cardiovascular events in women than in men. The Women's Health Study found that non-fasting triglycerides were a stronger independent predictor of incident cardiovascular events in women than total cholesterol. That sex difference is not fully explained, but estrogen's influence on very-low-density lipoprotein (VLDL) metabolism is part of the picture. Every hormonal shift across your life, from first period to menopause, changes how your liver produces and clears triglycerides.

How the Test Works

Your liver converts excess calories, especially from refined carbohydrates and alcohol, into triglycerides. Between meals, fat stored in adipose tissue is released as free fatty acids, which the liver repackages into VLDL particles carrying those triglycerides. Fasting for 9-12 hours clears most dietary (chylomicron) triglycerides from the bloodstream, leaving the VLDL-derived fraction. That is the number your clinician uses for risk stratification.

What Is a Normal Fasting Triglyceride Level?

The American Heart Association and the American College of Cardiology classify fasting triglycerides as follows:

| Category | Fasting Triglyceride Level | |---|---| | Desirable | <100 mg/dL | | Normal | <150 mg/dL | | Borderline high | 150-199 mg/dL | | High | 200-499 mg/dL | | Very high | 500 mg/dL or above |

Most labs flag anything at or above 150 mg/dL as "borderline high," but your personal treatment threshold depends on your full clinical picture, not one cut-off. A result of 160 mg/dL in a 28-year-old with no other risk factors calls for lifestyle counseling. The same result in a woman with type 2 diabetes and a prior cardiovascular event may change her medication list.

Desirable vs. "Normal": The Distinction That Matters

"Normal" in a lab report often means the population average, not the ideal value. The Endocrine Society's 2021 guideline on hypertriglyceridemia distinguishes between normal (under 150 mg/dL) and optimal (under 100 mg/dL) fasting triglycerides. For women with metabolic syndrome or PCOS, aiming for under 100 mg/dL rather than simply "under 150" is a reasonable clinical target.

What Your Number Actually Changes About Your Treatment

This is where fasting triglyceride results translate directly into prescribing decisions. The threshold matters, and so does the trajectory.

Under 150 mg/dL: No Medication, But Still Actionable

At this level, no triglyceride-specific drug is indicated. Your clinician focuses on lifestyle, statin therapy if your LDL or 10-year cardiovascular risk warrants it, and addressing any root cause such as insulin resistance or hypothyroidism. The ADA Standards of Care 2024 recommend lifestyle modification as first-line treatment for triglycerides in this range.

150-499 mg/dL: Secondary Causes Come First

Before adding a drug, your clinician should rule out:

• Uncontrolled type 2 diabetes or prediabetes
• Hypothyroidism (TSH above range)
• Poorly controlled PCOS with insulin resistance
• Alcohol use (even moderate intake raises triglycerides meaningfully)
• Certain medications including oral estrogen, tamoxifen, some antipsychotics, and corticosteroids

Once secondary causes are addressed, the Endocrine Society guideline recommends considering prescription omega-3 fatty acids (icosapentaenoic acid, EPA) when triglycerides remain above 150 mg/dL in a high-cardiovascular-risk patient. The REDUCE-IT trial (n = 8,179) showed that icosapentaenoic acid (Vascepa) 4 g/day reduced major cardiovascular events by 25% compared with placebo in patients with triglycerides between 135 and 499 mg/dL who were already on statins. Women made up only 29% of REDUCE-IT participants, a meaningful evidence gap; extrapolation to women is reasonable but directly studied data are limited.

500 mg/dL or Above: Pancreatitis Risk Changes Everything

A result at or above 500 mg/dL is a medical urgency, not simply a risk factor. At this level, the primary concern shifts from cardiovascular disease to acute pancreatitis, which can be life-threatening. Triglycerides above 1,000 mg/dL carry an estimated 5% risk of acute pancreatitis. Treatment becomes aggressive and multi-pronged:

• Immediate dietary fat restriction (under 15% of calories from fat)
• Elimination of alcohol
• Tight glycemic control if diabetes is present
• Fibrates (fenofibrate or gemfibrozil) as first-line drug therapy
• Prescription omega-3s as add-on therapy
• Referral to endocrinology or lipidology for genetic evaluation (familial hypertriglyceridemia or familial chylomicronemia syndrome)

Fibrates can lower triglycerides by 30-50% in women with severe hypertriglyceridemia. Gemfibrozil is generally avoided if a statin is already prescribed because of a meaningful rhabdomyolysis risk; fenofibrate carries a much lower interaction risk with statins and is preferred in that combination.

How Hormones and Life Stage Change Your Triglyceride Number

Across your reproductive life, hormonal shifts change triglyceride production, clearance, and interpretation. A single result needs context.

Reproductive Years and the Menstrual Cycle

Triglyceride levels fluctuate modestly across the menstrual cycle. Levels tend to be slightly higher in the luteal phase (after ovulation) compared with the follicular phase, likely due to progesterone-mediated changes in VLDL production. The difference is typically 10-20 mg/dL, not enough to change classification but worth knowing if you are tracking your own results over time. For most purposes, timing your lipid panel to the follicular phase (days 3-10 of your cycle) gives a more stable baseline, though this is not a formal guideline requirement.

PCOS and Insulin Resistance

PCOS is the most common endocrine disorder in reproductive-age women, affecting 8-13% of women of reproductive age. Insulin resistance, which is present in up to 70-80% of women with PCOS regardless of body weight, directly drives elevated VLDL production and higher fasting triglycerides. Women with PCOS frequently show the atherogenic dyslipidemia pattern: triglycerides above 150 mg/dL, low HDL, and normal to mildly elevated LDL. The AACE/ACE Comprehensive Diabetes Management Algorithm recommends fasting lipids at PCOS diagnosis and annually thereafter if triglycerides are above 150 mg/dL.

Treatment in PCOS prioritizes insulin sensitization. Metformin, lifestyle change, and weight loss (where applicable) can lower triglycerides by 10-20% in PCOS patients without adding a lipid-specific drug. Inositol supplementation (myo-inositol 4 g/day combined with D-chiro-inositol 400 mg) has shown modest triglyceride-lowering effects in small randomized trials, though the evidence base is not yet large enough for guideline inclusion.

Pregnancy: When High Is Expected But Still Monitored

Triglycerides rise dramatically in pregnancy. By the third trimester, values of 200-300 mg/dL are physiologically expected because your liver is producing more VLDL to support fetal lipid delivery. The American College of Obstetricians and Gynecologists does not recommend routine triglyceride screening in uncomplicated pregnancies, but values above 400 mg/dL in the third trimester warrant specialist evaluation because the risk of gestational pancreatitis rises sharply.

Women with pre-existing hypertriglyceridemia (especially above 500 mg/dL preconception) should be co-managed by maternal-fetal medicine and lipidology throughout pregnancy. Most triglyceride-lowering drugs, including fibrates, prescription omega-3 fatty acids, and niacin, have insufficient human safety data in pregnancy and are generally avoided except in cases of extreme risk. Dietary fat restriction remains the safest intervention.

Postpartum and Lactation

Triglycerides typically fall back toward pre-pregnancy baseline by 6 weeks postpartum. Breastfeeding is associated with modestly lower triglycerides compared with formula feeding, though the magnitude is small and confounded by caloric intake. If triglycerides remain elevated at the 6-week or 3-month postpartum visit, this warrants workup for postpartum thyroiditis (which affects 5-10% of women in the first year after delivery) as a contributing cause, before attributing the result to primary dyslipidemia.

Fenofibrate is present in breast milk in animal studies; human lactation data are insufficient, and most clinicians avoid it during breastfeeding. Prescription omega-3 (EPA/DHA) supplementation is generally considered compatible with breastfeeding, though the high-dose pharmaceutical form (Vascepa, 4 g/day) has not been formally studied in lactation.

Perimenopause

The perimenopausal transition (typically ages 45-55, but often beginning in the early 40s) brings rising triglycerides independent of diet or weight change. Estradiol suppresses hepatic VLDL production; as estradiol levels become erratic and eventually fall, that suppression lifts. The SWAN study found that triglycerides increased by an average of 14.7 mg/dL across the menopause transition, with the steepest rise in the 2 years surrounding the final menstrual period. If your triglycerides were stable at 130 mg/dL in your early 40s and are now 175 mg/dL at age 50, menopause physiology is likely contributing, not simply lifestyle changes.

Postmenopause and Hormone Therapy: A Critical Prescribing Consideration

This is one of the most clinically specific decisions your triglyceride level shapes.

Oral estrogen raises triglycerides. Oral estrogen undergoes first-pass hepatic metabolism, which stimulates VLDL production. In women with baseline triglycerides above 150-200 mg/dL, adding oral estrogen (estradiol tablets or conjugated equine estrogen) may push values into the borderline-high or high range, and in women with pre-existing hypertriglyceridemia, it can precipitate severe hypertriglyceridemia and pancreatitis.

Transdermal estradiol avoids first-pass metabolism and does not raise triglycerides. The ESTHER study found that transdermal estradiol, unlike oral estrogen, did not increase triglycerides and was associated with a lower risk of venous thromboembolism. The Menopause Society (NAMS) 2022 position statement specifies that transdermal estradiol is preferred for women with elevated triglycerides, hypertension, or high VTE risk.

Practical implication: if your fasting triglycerides are above 150 mg/dL and you need hormone therapy for menopause symptoms, your clinician should prescribe transdermal estradiol, not oral estrogen, and recheck triglycerides at 6-12 weeks.

How to Lower Fasting Triglycerides: The Evidence-Based Sequence

Lifestyle changes move this number meaningfully and quickly.

Dietary Changes That Work

• Reduce refined carbohydrates and added sugar. Simple carbohydrates drive hepatic lipogenesis more than dietary fat does. A meta-analysis of 89 trials found that replacing 5% of energy from carbohydrates with unsaturated fat lowered triglycerides by approximately 6 mg/dL.
• Cut alcohol. Even two drinks per day raise fasting triglycerides substantially. The effect is dose-dependent and reversible within 1-2 weeks of abstinence.
• Eat fatty fish or take omega-3 supplements. At over-the-counter doses (1 g/day of EPA plus DHA), triglycerides fall by roughly 5-10%. At prescription doses (4 g/day of EPA alone), the reduction can reach 20-30% from baseline.
• Reduce fruit juice and fructose. Fructose is metabolized almost entirely in the liver and is a potent driver of VLDL production.

Physical Activity

Aerobic exercise reduces triglycerides by increasing lipoprotein lipase activity, the enzyme that clears VLDL from the bloodstream. A meta-analysis in the British Journal of Sports Medicine found that 150 minutes per week of moderate-intensity aerobic activity lowered triglycerides by an average of 10 mg/dL in adults with elevated levels.

GLP-1 Receptor Agonists

GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) significantly lower fasting triglycerides through a combination of weight loss and direct effects on hepatic lipid metabolism. In the STEP 1 trial, semaglutide 2.4 mg weekly reduced fasting triglycerides by approximately 20 mg/dL compared with placebo at 68 weeks. For women with PCOS and elevated triglycerides who also need weight management, this class can address both targets simultaneously.

Metformin in Insulin-Resistant Women

In women with PCOS or prediabetes, metformin lowers fasting triglycerides modestly (typically 10-15 mg/dL) by reducing hepatic glucose output and secondarily reducing VLDL synthesis. It is not a primary triglyceride-lowering drug, but for women where insulin resistance is the driver, treating the root cause is more durable than adding a lipid drug.

Conditions That Raise Triglycerides: What to Rule Out First

Before attributing elevated triglycerides to diet or genetics, your clinician should check:

• Thyroid function (TSH). Hypothyroidism raises triglycerides. Postpartum thyroiditis affects up to 10% of women in the first year after delivery and is a common reversible cause of postpartum dyslipidemia.
• Fasting glucose and HbA1c. Uncontrolled diabetes is one of the most common secondary causes of hypertriglyceridemia.
• Kidney function (creatinine, eGFR). Chronic kidney disease raises triglycerides.
• Medication review. Oral estrogen, tamoxifen, raloxifene (to a lesser degree), atypical antipsychotics (especially olanzapine and clozapine), and systemic corticosteroids all raise triglycerides. If a woman on tamoxifen develops triglycerides above 300 mg/dL, her oncology team needs to know; some switch to an aromatase inhibitor, which has a more neutral lipid profile.

Who Should Be Tested and How Often

The USPSTF recommends lipid screening for women at increased cardiovascular risk beginning at age 45, and for all women at 55. Women with PCOS, type 2 diabetes, a family history of premature cardiovascular disease, or a prior history of gestational diabetes or hypertensive disorders of pregnancy should be screened earlier, starting between ages 20 and 30.

Retesting frequency after an abnormal result:

• Borderline high (150-199 mg/dL): retest after 3 months of lifestyle change
• High (200-499 mg/dL): retest at 6-12 weeks if a secondary cause has been addressed, or sooner if a new drug is started
• Very high (500 mg/dL or above): retest within 4-6 weeks of initiating treatment

Pregnancy and Lactation Considerations

Fasting triglycerides do not typically require drug treatment during pregnancy, even when values are high, because most triglyceride-lowering medications carry safety concerns that outweigh the benefit in the absence of imminent pancreatitis risk.

Fibrates (fenofibrate, gemfibrozil): Category C by historical classification. Animal studies show developmental toxicity. Human data are insufficient. Avoid in pregnancy except in life-threatening hypertriglyceridemia (generally above 1,000 mg/dL with pancreatitis risk) under specialist guidance.

Prescription omega-3 fatty acids (Vascepa, Lovaza): No controlled human pregnancy data. Omega-3 fatty acids cross the placenta; DHA in particular is important for fetal brain development. The pharmaceutical-dose EPA-only product (Vascepa) has not been studied in pregnancy. Dietary omega-3 from low-mercury fish is considered safe and is recommended by ACOG.

Niacin: Avoid in pregnancy. Associated with fetal harm in animal studies.

Statins: Contraindicated in pregnancy. Not triglyceride-specific drugs, but commonly co-prescribed; women of reproductive age on statins need reliable contraception and should stop statins before conception.

Dietary management is the cornerstone. Limiting fat intake to under 15% of total calories, eliminating alcohol, and maintaining tight blood sugar control can lower triglycerides meaningfully without medication.

During lactation, dietary omega-3 supplementation at 1-2 g/day of combined EPA and DHA is compatible with breastfeeding and is beneficial for infant neurodevelopment. High-dose pharmaceutical omega-3 products and fibrates should be avoided while breastfeeding pending more human data.

Tracking Your Results Over Time

A single fasting triglyceride measurement is less informative than a trend. Lab-to-lab variability (biological plus analytical) means that a 10-15% change in either direction may not represent a true physiological change. Clinically meaningful shifts are generally 20% or more from a confirmed baseline. When tracking your own numbers:

• Use the same laboratory if possible, because reference method calibration varies across labs
• Draw the sample at a similar phase of your menstrual cycle if you are premenopausal
• Note any changes in diet, alcohol intake, new medications, or major stress, all of which shift the result independently of underlying disease